Arterra Bioscience (ARBS) H1 2025 earnings summary

Executive summary

• Net profit reached €1,085,225 for the six months ended June 30, 2025, more than doubling year-over-year from €517,261.

• Production value rose to €3,142,012, a 35.5% increase year-over-year.

• EBITDA rose 143% to €1,200,000, with margin improving to 37.6% from 21.0% a year earlier.

• Strong cash position with €3,442,220 in liquid assets at period end.

• Equity increased to €11,700,000 from €11,400,000 at December 2024.

Financial highlights

• Revenue from sales and services rose to €2,572,169, a 15% increase compared to the same period last year.

• Operating costs increased to €2,101,817, mainly due to higher personnel and R&D service expenses.

• Cash flow from operations was €1,530,000, up from €690,000 in H1 2024.

• Investments in tangible and intangible assets totaled €403,103 in H1 2025.

• Dividends from Vitalab S.r.l. contributed €144,236 to financial income.

Outlook and guidance

• Management optimistic about meeting 2025 growth targets, supported by strong first-half sales and robust order backlog.

• Advanced R&D projects are expected to deliver innovative products to market in the near future.